

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/014806-2021>

Tender

Logic Model and Impact Evaluation Methodology

Medicines Discovery Catapult

F02: Contract notice

Notice identifier: 2021/S 000-014806

Procurement identifier (OCID): ocds-h6vhtk-02c149

Published 29 June 2021, 11:59am

Section I: Contracting authority

I.1) Name and addresses

Medicines Discovery Catapult

Block 35, Mereside, Alderley Park

Cheshire

SK10 4TG

Contact

Mr Kieran McGowan

Email

Kieran.McGowan@md.catapult.org.uk

Telephone

+44 1625708394

Country

United Kingdom

NUTS code

UKD62 - Cheshire East

Internet address(es)

Main address

<https://md.catapult.org.uk/>

Buyer's address

<https://md.catapult.org.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545>

I.4) Type of the contracting authority

Other type

Research - Drug Discovery / Health

I.5) Main activity

Other activity

Research - Drug Discovery / Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Logic Model and Impact Evaluation Methodology

Reference number

DN553327

II.1.2) Main CPV code

- 79000000 - Business services: law, marketing, consulting, recruitment, printing and security

II.1.3) Type of contract

Services

II.1.4) Short description

The Catapult Centres are a network of world-leading centres designed to transform the UK's capability for innovation in specific areas and help drive future economic growth.

(<https://catapult.org.uk/catapult-centres/>). Our specific area is medicines discovery.

Part-funded by Innovate UK, an agency of the UK government, we are an independent not-for-profit company. We bring together industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high-value products.

MDC is a national facility connecting the UK community to accelerate innovative drug discovery.

We provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.

By validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK's heritage position as a global leader in medicines R&D.

MDC is currently in year 4 of our first 5-year grant funding agreement, referred to (GFA 1). To support our GFA1 evaluation, we have a logic model outlining our theory of change,

and a supporting evaluation methodology framework, which we are in the process of implementing.

In parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.

The estimated value is between £20,000.00 and £35,000.00.

Link to ITT documents here: <https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545>

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.3) Place of performance

NUTS codes

- UKD62 - Cheshire East

II.2.4) Description of the procurement

The Catapult Centres are a network of world-leading centres designed to transform the UK's capability for innovation in specific areas and help drive future economic growth.

(<https://catapult.org.uk/catapult-centres/>). Our specific area is medicines discovery.

Part-funded by Innovate UK, an agency of the UK government, we are an independent not-for-profit company. We bring together industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high-value products.

MDC is a national facility connecting the UK community to accelerate innovative drug discovery.

We provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.

By validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK's heritage position as a global

leader in medicines R&D.

MDC is currently in year 4 of our first 5-year grant funding agreement, referred to (GFA 1). To support our GFA1 evaluation, we have a logic model outlining our theory of change, and a supporting evaluation methodology framework, which we are in the process of implementing.

In parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.

The estimated value is between £20,000.00 and £35,000.00.

Link to ITT documents here: <https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545>

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £35,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

End date

31 October 2021

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

9 July 2021

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date

9 July 2021

Local time

12:05pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

Medicines Discovery Catapult

Block 35, Mereside, Alderley Park

Cheshire

SK10 4TG

Email

kieran.mcgowan@md.catapult.org.uk

Country

United Kingdom